What Is Sulanemadlin? Definition and What Research Reports

Definition

Sulanemadlin is the international nonproprietary name of an investigational synthetic peptide that also appears in the literature under the code ALRN-6924. It is a chemically stabilized, cell-permeating alpha-helical peptide designed to bind the p53-binding pockets of the proteins MDM2 and MDMX, and researchers who published its discovery described it as the first cell-permeating, stabilized alpha-helical peptide to reach clinical development (PMID 37439511). In short, the word refers to a specific named molecule from the “stapled peptide” class, not to a category of compounds, a hormone analogue, or a dietary ingredient.

What Class of Molecule It Is

Sulanemadlin belongs to the family usually called stapled peptides or stabilized alpha-helical peptides. These are fully synthetic peptides in which a chemical cross-link — the “staple” — is installed between side chains so that the chain is locked into a helical shape rather than sampling many flexible conformations. The stated design goals for this class are a more rigid, protease-resistant helix and the ability to cross cell membranes, which is unusual for peptides, since most peptide drugs act on targets outside the cell. The discovery report for sulanemadlin presented it as the clinical-stage example of that design approach (PMID 37439511).

Where It Comes From

The molecule is laboratory-made. It is not extracted from tissue, not a fragment of a naturally circulating human hormone, and not a modified version of an endogenous signalling peptide such as a growth-hormone secretagogue. Its origin is a medicinal-chemistry programme: the 2023 Journal of Medicinal Chemistry paper documented the discovery of sulanemadlin as a designed, optimized stapled peptide rather than a natural product (PMID 37439511).

Why MDM2 and MDMX Are the Named Targets

MDM2 and MDMX (also written MDM4) are the two principal negative regulators of p53, a tumour-suppressor transcription factor. In cells where the TP53 gene is intact — described in the oncology literature as “wild-type p53” — blocking both regulators is the pharmacological rationale for restoring p53 activity. Sulanemadlin is referred to throughout the literature as a dual MDM2/MDMX inhibitor, and a 2024 preclinical study in iScience examined that dual inhibition specifically in wild-type p53 tumours (PMID 38784022).

How the Term Is Used in Peptide Research

The name appears in three broad contexts in the published literature:

• As a chemistry case study. Writers on peptide design cite sulanemadlin when discussing whether peptides can be engineered to hit intracellular protein–protein interactions, a target class often labelled “undruggable” by small molecules; the discovery paper framed it exactly that way (PMID 37439511).
• As an oncology tool compound. Preclinical cancer-biology papers use it to probe what happens when MDM2 and MDMX are inhibited together, including in combination with immune checkpoint blockade (PMID 38784022).
• As an example in peptide-developability reviews. Reviews of how peptide therapeutics are metabolized and how developers address that problem survey strategies and case studies that moved peptides toward clinical success, which is the same developability question stapled-peptide chemistry is meant to answer (PMID 41348552).

It is worth stating plainly what the term is not used for. Sulanemadlin is not described in the cited literature as a metabolic, cosmetic, recovery, or performance peptide, and none of the sources in this entry evaluated it in healthy volunteers for any such purpose.

Quick Reference

What the Published Literature Reports

The discovery report (2023)

The 2023 Journal of Medicinal Chemistry article set out the discovery of sulanemadlin and characterised it as the first cell-permeating, stabilized alpha-helical peptide in clinical development (PMID 37439511). The significance researchers attached to that description is structural rather than therapeutic: it marks the point at which a stapled peptide moved from a chemistry concept into human study.

The combination preclinical study (2024)

A 2024 study published in iScience investigated MDM2/MDMX inhibition by sulanemadlin together with anti-programmed death 1 (anti-PD-1) immunotherapy in wild-type p53 tumours, and the study reported synergy between the two approaches in that setting (PMID 38784022). That work is preclinical in scope, and the p53 status of the tumour model was an explicit condition of the finding rather than an incidental detail.

The peptide-metabolism review (2025)

A 2025 review in Journal of Medicinal Chemistry addressed the metabolic challenges facing peptide therapeutics and compiled strategies and case studies associated with clinical success (PMID 41348552). Reviews of this type supply the context in which stapling is discussed — peptides are, as a class, vulnerable to proteolysis, and conformational constraint is one of the engineering answers to that problem.

Safety and Tolerability: What Studies Report

None of the three sources indexed in this entry is a clinical safety report. The 2023 paper is a discovery and characterisation article (PMID 37439511), the 2024 paper is a preclinical combination study in tumour models (PMID 38784022), and the 2025 paper is a review of peptide metabolism strategies (PMID 41348552). Because no adverse-event dataset falls within the verified scope of this entry, no adverse-event frequencies, no tolerability conclusions and no dose levels are summarised here. The absence of such a summary on this page should not be read as evidence that a compound is well tolerated; it means the question was not covered by the sources cited.

Limits of This Entry

This is a definitional glossary stub. It does not describe dosing, schedules, routes of administration, combinations for any individual, or outcomes in named populations, because those details are outside the scope of the papers cited above. Investigational agents in oncology are studied under clinical trial protocols with physician oversight, diagnostic criteria and monitoring; a glossary definition is not a substitute for any part of that. Readers comparing sulanemadlin to peptides discussed in consumer settings should note the difference in category: this is an investigational anticancer agent aimed at an intracellular protein–protein interaction, and the literature treats it accordingly.

This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified healthcare professional about any medical question, medication or investigational agent.

References

• Discovery of Sulanemadlin (ALRN-6924), the First Cell-Permeating, Stabilized α-Helical Peptide in Clinical Development (Journal of Medicinal Chemistry, 2023)
• MDM2/MDMX inhibition by Sulanemadlin synergizes with anti-Programmed Death 1 immunotherapy in wild-type p53 tumors (iScience, 2024)
• Overcoming Challenges in the Metabolism of Peptide Therapeutics: Strategies and Case Studies for Clinical Success (Journal of Medicinal Chemistry, 2025)